How does your approach differ when managing a "triple hit" versus a "double hit" or "double expressor" lymphoma?
Given the rarity of DLBCL with MYC/BCL2/BCL6 rearrangements, do you approach this disease differently than DLBCL with MYC/BCL2 or BCL6 rearrangement, or DLBCL with MYC/BCL2 or BCL6 overexpression?
Answer from: Medical Oncologist at Academic Institution
Double-hit lymphoma and double-expressing lymphoma are biologically and clinically distinct entities. DHL is now classified within the WHO as high-grade lymphoma, and the majority are of germinal center immunophenotype, whereas DEL is most typically of non-germinal center immunophenotype and classif...
Sign in or Register to read more